AMY EVANS-KEGLEY: Open Payments
NPI 1447975032 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$434 in 22 payments from 16 companies in 2025. Trend: 2023 $555 · 2024 $719 · 2025 $434
Food & beverage: $434
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $60 |
| PFIZER INC. | 3 | $51 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Gilead Sciences, Inc. | 1 | $27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 |
| Amgen Inc. | 1 | $21 |
| Verona Pharma, Inc. | 1 | $21 |
| Cranial Technologies, Inc | 1 | $21 |
Products named: VRAYLAR, AIRSUPRA, JARDIANCE, NURTEC ODT, CAPLYTA, ZORYVE, OTEZLA, Ohtuvayre.
Industry payments across MD — which companies pay providers there.
